Ann: First Australian Patient Dosed in Phase 1b azer-cel Trial, page-88

My argument will LC and PH announce the news to satisfy traders? is this why IMU is doing clinical trials? we need to understand why IMU is company in first place, do not counter argue to make money to PH. LC yada yada yada thats also true in some sense, we happen to invest to make money ( some good souls here do not hold still are concerned about the holder, god bless their soul, in modern world they are called shorters )

Trials are very dynamic, early timelines are based on estimates, and unexpected complexities will arise during data analysis or trial progression, for example if CF33 was found to be more effective when combined with a CAR T-cell therapy like Azer-cel , this would likely have to be/been determined after analysing initial trial result, acquisition of Azercel wasn't necessarily a sign that CF33 couldn't work alone, it could be an effort to enhance efficacy or broaden treatment options, Companies are not obligated to disclose every individual result unless it is material for example a major breakthrough or safety concern, early news of a complete response was a strategic choice to show the trial’s potential and may be to boost investor confidence as companies try to show why they acquired something with some early results , if you have invested in clinical stage biotech you should be ready for delays, adjustments, and strategic changes and its part of the process.

Having said all this, I too get impatient, I too doubt, I too think to move on.. then I read above..